<DOC>
	<DOC>NCT01593332</DOC>
	<brief_summary>In this project the investigators decide to evaluate the efficacy and safety of half dose mabthera (it means 500 mg infusion two weeks apart) in conventional drug resistant cases of rheumatoid arthritis. The investigators choose this drug because the use of anti-TNF drugs limited in the investigators refractory patients as the first line drugs because of its cost.</brief_summary>
	<brief_title>Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1987 ACR criteria for classification of RA Positive for rheumatoid factor(RF) Active RA despite therapy with conventional for at least 3 months as evidenced by DAS 28 &gt; 3/2 Patients with active, resistant RA who didn't receive anti TNF agents. Patient with hypogammaglobulinemia Patient with congestive heart failure (classIV) Active current bacterial,viral,fungal,myocardial or other infections Chronic hepatitis B or hepatitis C carriers History of severe allergic reaction to human,humanized or murine monoclonal antibodies History of malignancies Pregnant women or lactating mothers 8) Patients with Chronic renal failure and hepatic disease.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Biologics</keyword>
	<keyword>Anti-tumour necrosis factor</keyword>
	<keyword>Disease-modifying anti-rheumatic drugs</keyword>
	<keyword>DAS28</keyword>
	<keyword>European League Against Rheumatism response</keyword>
</DOC>